OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma - PubMed (original) (raw)

. 2010 Sep 2;467(7311):86-90.

doi: 10.1038/nature09284. Epub 2010 Aug 8.

Affiliations

OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma

Pedro P Medina et al. Nature. 2010.

Abstract

MicroRNAs (miRNAs) belong to a recently discovered class of small RNA molecules that regulate gene expression at the post-transcriptional level. miRNAs have crucial functions in the development and establishment of cell identity, and aberrant metabolism or expression of miRNAs has been linked to human diseases, including cancer. Components of the miRNA machinery and miRNAs themselves are involved in many cellular processes that are altered in cancer, such as differentiation, proliferation and apoptosis. Some miRNAs, referred to as oncomiRs, show differential expression levels in cancer and are able to affect cellular transformation, carcinogenesis and metastasis, acting either as oncogenes or tumour suppressors. The phenomenon of 'oncogene addiction' reveals that despite the multistep nature of tumorigenesis, targeting of certain single oncogenes can have therapeutic value, and the possibility of oncomiR addiction has been proposed but never demonstrated. MicroRNA-21 (miR-21) is a unique miRNA in that it is overexpressed in most tumour types analysed so far. Despite great interest in miR-21, most of the data implicating it in cancer have been obtained through miRNA profiling and limited in vitro functional assays. To explore the role of miR-21 in cancer in vivo, we used Cre and Tet-off technologies to generate mice conditionally expressing miR-21. Here we show that overexpression of miR-21 leads to a pre-B malignant lymphoid-like phenotype, demonstrating that mir-21 is a genuine oncogene. When miR-21 was inactivated, the tumours regressed completely in a few days, partly as a result of apoptosis. These results demonstrate that tumours can become addicted to oncomiRs and support efforts to treat human cancers through pharmacological inactivation of miRNAs such as miR-21.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Blood. 2009 Aug 13;114(7):1374-82 - PubMed
    1. Cancer Res. 2005 Aug 15;65(16):7065-70 - PubMed
    1. Blood. 2008 Mar 1;111(5):2825-32 - PubMed
    1. Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12085-90 - PubMed
    1. Cell Res. 2008 Mar;18(3):350-9 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources